Merck News (NYSE:MRK)

DateTimeSource
Headline
06/28/20177:24AMDJNToday's Top Supply Chain and Logistics News From WSJ
By Paul Page Sign up: With one click, get this newsletter delivered to your inbox. The world-wide cyberattacks that have plagued corporations are hitting the shipping business in a big way. Container shipping giant Maersk Line was among a raft of global companies and institutions that were crippled by a virus similar to... More...>>
06/27/20171:49PMDJNMerck Says Its Network Was Hit by Global Hack
By Joseph Walker Merck & Co., one of the world's largest pharmaceutical companies, said in a series of Twitter posts that its "computer network was compromised today as part of global hack," and noted that "other organizations have also been affected." The company, based in Kenilworth, N.J... More...>>
06/27/20176:55AMBWMerck Provides Update on REVEAL Outcomes Study of Anacetrapib
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its primary endpoint, significantly reducing major coronary events (defined as the composite of coronary... More...>>
06/22/20178:48AMBWMerck and Premier Inc. Expand Collaboration to Address Chronic Care and Vaccination Rates
Call for health systems to join initiatives to improve care for specific patient populations Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have expanded their efforts to co-develop and test solutions to help improve patient... More...>>
06/12/20174:15PMBWMerck Provides Update on Multiple Myeloma Studies KEYNOTE-183 & 185 of KEYTRUDA® (pembrolizumab) in Combination with Other T...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on two combination studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. Merck has accepted the external Data Monitoring Committee recommendation to pause new enrollment... More...>>
06/10/20171:00PMBWMerck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies
Ertugliflozin as Add-on to Metformin or in Initial Co-administration with Sitagliptin Showed Significant A1C Reductions in Adults with Type 2 Diabetes Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS MET and... More...>>
06/05/20177:30AMBWUpdated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck’s KEYTRUDA® (pembrolizumab) Compared to Che...
Longer-Term Findings to Be Presented at 2017 ASCO Annual Meeting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated overall survival (OS) findings from KEYNOTE-024, the phase 3 study evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy compared... More...>>
06/05/20177:05AMBWNew Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck’s KEYTRUDA® (pembrolizumab) Plus Sta...
Data to Be Presented at 2017 ASCO Annual Meeting Include Findings in Patients with Locally Advanced Triple-Negative (TNBC) and Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Breast Cancers Merck (NYSE:MRK), known as MSD outside the United States and Canada, and QuantumLeap Healthcare Collaborative, today announced... More...>>
06/05/20177:00AMBWUpdated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstra...
Responses observed with combination of IDO1 enzyme inhibition and anti-PD-1 therapy support advancing into broad Phase 3 program Safety data for this novel investigational immunotherapy combination are generally similar to KEYTRUDA monotherapy Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside... More...>>
06/04/201710:00AMBWNew Monotherapy Data for Merck’s KEYTRUDA® (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from Cohort 1 of the phase 2 registrational KEYNOTE-059 trial investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as monotherapy in previously-treated patients with advanced gastric or gastroesophageal... More...>>
06/04/20179:00AMBWWith More than One-Year Follow-Up, Merck’s KEYTRUDA® (pembrolizumab) Shows Continued Overall Survival Benefit Over Chemoth...
Findings to Be Presented at 2017 ASCO Annual Meeting Also Include Updated Data Evaluating Duration of Response in Previously Untreated (First-Line) Urothelial Carcinoma Patients Ineligible for Cisplatin-Based Therapy Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from... More...>>
06/03/20179:00AMBWCombination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Pa...
Updated Phase 1/2 data from ECHO-202 investigating the combination of IDO1 enzyme inhibition and anti-PD-1 therapy in patients with advanced NSCLC, regardless of PD-L1 status, presented at 2017 ASCO Annual Meeting Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada... More...>>
06/03/20178:30AMBWNew Data Show Durability of Response for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Microsatellite Instability-High (MS...
First-Time Findings from KEYNOTE-164 and KEYNOTE-158, to Be Presented at ASCO, Further Support the Utility of MSI-H and dMMR as Predictive Biomarkers for Tumor-Agnostic Treatment Approach with KEYTRUDA Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of findings... More...>>
06/03/20178:00AMBWLonger Term Follow-Up Data with Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed & Carboplatin in First-Li...
Data Include Overall Response Rate, Progression-Free Survival and Overall Survival Findings from Additional Five Months of Follow-Up in KEYNOTE-021 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated results from KEYNOTE-021, Cohort G1, which studied KEYTRUDA® (pembrolizumab... More...>>
06/02/20178:19AMDJNMerck reports positive results for late-stage trial comparing its Keytruda against Bristol-Myers' Yervoy -- MarketWatch
Merck & Co. Inc. (MRK) said premarket Friday that a late-stage clinical trial comparing its cancer drug Keytruda to Bristol-Myers Squibb's [: BMY] cancer drug Yervoy found patients on Keytruda had better results. The trial, which enrolled 834 patients with unresectable or metastatic melanoma who were either new... More...>>
06/02/20177:30AMBWWith Nearly Three Years of Follow-Up, KEYTRUDA® (pembrolizumab) Data Demonstrated Improved Survival Benefit Compared to Ipil...
Findings Show Durable Responses with KEYTRUDA after Treatment Concluded: 91 Percent of Patients Who Discontinued Treatment at Two Years Were Alive Without Progression of Disease after a Median Follow-Up of Nearly 10 Months Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated longer-term... More...>>
06/01/20178:00AMBWMerck to Present at the Bernstein’s 33rd Annual Strategic Decisions Conference
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, is scheduled to present at the Bernstein’s 33rd Annual Strategic Decisions Conference in New York on June 2, 2017 at 10:00 a.m. EDT. Investors, analysts, members of the media... More...>>
05/30/20178:00AMBWMerck Highlights Ongoing Commitment to Fighting Infectious Diseases With More than 20 Data Presentations at ASM Microbe 2017
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 20 scientific data presentations on the company’s established and investigational infectious disease medicines at the American Society for Microbiology’s ASM Microbe 2017 meeting... More...>>
05/30/20177:00AMBWMerck Receives FDA Approval of ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretrovira...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ISENTRESS® HD, a new 1200 mg once-daily dose of the company’s integrase inhibitor, ISENTRESS® (raltegravir), to be administered orally as two 600 mg film-coated tablets... More...>>
05/29/201712:55PMDJNCongo Approves Anti-Ebola Vaccine to Combat Outbreak in Remote Northeast
By Nicholas Bariyo KAMPALA, Uganda--The Democratic Republic of the Congo on Monday approved the use of a new experimental Ebola vaccine, nearly three weeks after health officials announced the latest outbreak of the deadly virus along the country's northeastern border. The approval was granted by Congo's health... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V:us D:20170629 01:58:18